| Schedule of segment reporting |
| Schedule of segment reporting |
|
|
|
|
|
|
|
|
| |
|
For the
Six Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| Revenue |
|
$ |
- |
|
|
$ |
39,990 |
|
| |
|
|
|
|
|
|
|
|
| Less: Significant and other segment expenses: |
|
|
|
|
|
|
|
|
| NEO100 |
|
|
1,881,023 |
|
|
|
688,628 |
|
| NEO100-02 |
|
|
409,338 |
|
|
|
201,787 |
|
| NEO212 |
|
|
861,334 |
|
|
|
455,629 |
|
| NEO216 |
|
|
75,336 |
|
|
|
- |
|
| Pediatric |
|
|
167,009 |
|
|
|
99,010 |
|
| Laboratory |
|
|
470,930 |
|
|
|
192,377 |
|
| Other |
|
|
71,039 |
|
|
|
38,123 |
|
| Total research and development expense |
|
|
3,936,009 |
|
|
|
1,675,554 |
|
| |
|
|
|
|
|
|
|
|
| Advisory fees – related parties |
|
|
4,946,575 |
|
|
|
11,737,806 |
|
| Legal and professional |
|
|
2,474,387 |
|
|
|
1,477,909 |
|
| Employee compensation expenses |
|
|
458,025 |
|
|
|
334,160 |
|
| Amortization of debt issuance |
|
|
360,116 |
|
|
|
360,200 |
|
| Investor relations |
|
|
104,322 |
|
|
|
771,073 |
|
| Stock based compensation |
|
|
8,384,311 |
|
|
|
20,923,850 |
|
| Other general and administrative expense |
|
|
821,920 |
|
|
|
728,514 |
|
| Interest expense |
|
|
1,216,994 |
|
|
|
357,672 |
|
| Loss on change in fair value of derivative liability related to Series A preferred stock |
|
|
61,321 |
|
|
|
- |
|
| Gain on change in fair value of derivative liability |
|
|
(2,801 |
) |
|
|
- |
|
| Other expense |
|
|
834,228 |
|
|
|
(240,138 |
) |
| Interest and other income |
|
|
(535,431 |
) |
|
|
(80,424 |
) |
| Net loss |
|
$ |
(23,059,976 |
) |
|
$ |
(38,006,186 |
) |
| |
|
|
|
|
|
|
|
|
| |
|
For the
Three Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| Revenue |
|
$ |
- |
|
|
$ |
- |
|
| |
|
|
|
|
|
|
|
|
| Less: Significant and other segment expenses: |
|
|
|
|
|
|
|
|
| NEO100 |
|
|
998,369 |
|
|
|
109,166 |
|
| NEO100-02 |
|
|
304,244 |
|
|
|
93,326 |
|
| NEO212 |
|
|
592,757 |
|
|
|
279,074 |
|
| NEO216 |
|
|
75,336 |
|
|
|
- |
|
| Pediatric |
|
|
147,273 |
|
|
|
50,178 |
|
| Laboratory |
|
|
460,655 |
|
|
|
107,465 |
|
| Other |
|
|
71,039 |
|
|
|
38,123 |
|
| Total research and development expense |
|
|
2,649,673 |
|
|
|
677,332 |
|
| |
|
|
|
|
|
|
|
|
| Advisory fees – related parties |
|
|
3,586,575 |
|
|
|
- |
|
| Legal and professional |
|
|
1,286,167 |
|
|
|
520,364 |
|
| Employee compensation expenses |
|
|
268,797 |
|
|
|
163,887 |
|
| Amortization of debt issuance |
|
|
167,951 |
|
|
|
192,249 |
|
| Investor relations |
|
|
56,810 |
|
|
|
226,766 |
|
| Stock based compensation |
|
|
5,651,913 |
|
|
|
3,526,076 |
|
| Other general and administrative expense |
|
|
569,952 |
|
|
|
593,609 |
|
| Interest expense |
|
|
234,370 |
|
|
|
48,750 |
|
| Loss on change in fair value of derivative liability related to Series A preferred stock |
|
|
61,321 |
|
|
|
- |
|
| Other expense |
|
|
189,627 |
|
|
|
(240,138 |
) |
| Interest and other income |
|
|
(483,112 |
) |
|
|
(28,725 |
) |
| Net loss |
|
$ |
(14,240,044 |
) |
|
$ |
(5,680,170 |
) |
|